Radbio

Our main focus is on fibrosis, which plays an important role in the cause of death of many diseases, and despite the existence of drugs that can delay its progression, current treatments are unable to stop or reverse the disease's progression. One of the main drivers of fibrosis is TGF-β, a cytokine known as the “Master Regulator of fibrosis”, which is dysregulated in several diseases. At RADBIO we have developed a novel therapeutic platform focused on this key player, that is: TGF-β. We discovered a new human protein, which is a novel soluble splice variant of the TGF-beta receptor 2, and with genetic engineering, we are capable of develop new assets. Depending on the target indications we can design and develop the new assets and delivery strategies. This not only increases the potential areas of application, bue also reduces risk and increases value.